Advancing drug discovery with nearly 50 years of proven experience.
Leveraging our technical expertise to create a future of accessible treatments.
Though Mediford in its current form was founded in 2023, our journey began in 1977. Since those first steps into non-clinical study services, Mediford has spent nearly half a century at the cutting edge of drug discovery and development, including analytical studies in the clinical trial field. The extensive experience and sophisticated techniques we have built over these decades are our greatest pride and the foundation of the deep trust we share with our clients.
The landscape of drug discovery and development is currently in a period of dramatic transformation. Leveraging our core strength in technical expertise, we are actively addressing new modalities such as nucleic acid therapeutics and cell therapies. From advanced analytical method development to drug safety and efficacy evaluation, we continue to pursue state-of-the-art technology in Japan to provide robust support for drug discovery and development globally.
Our mission goes beyond simply providing test data.
We are dedicated to tackling the challenges of "drug lag" and "drug loss" ― the delays and unavailability of innovative medicines. By helping to ensure that advanced pharmaceuticals and treatments reach patients as quickly and reliably as possible, we aim to contribute to a society where health and well-being are available to all.
At Mediford, we can.
We look forward to your continued support and high expectations for the future of Mediford.
Tetsuya Ueda
President
Mediford Corporation